ArticleCancer immunology, immunotherapy : CII2020

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.

Laura A Vitale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.